


P-UNILU-001/WO

CLAIMS

1. Compounds of the general Formula (I):



wherein

- 5 - R₁, R₂, R₃ and R₄, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C₁-C₆) alkyl group, a linear or branched (C₁-C₆) alkoxy group, a linear or branched (C₁-C₆) carboxylate group,
- 10 - R₅ represents a hydrogen atom or a linear or branched (C₁-C₆) alkyl group,
- 15 - m is an integer between 1 and 2, and
- 16 - n is an integer between 8 and 20.

2. Compounds according to Claim 1, wherein n is an integer between 8 and 16.

15

3. Compounds according to Claim 2, wherein n is an integer equal to 8, 10, 12, 13, 14 or 16.

20


4. Compounds according to Claim 1, wherein the compound is a compound selected from TFA12, TFA14, TFA15, TFA16 and TFA18.

5. Compounds according to any of the preceding Claims, wherein R₅ represents a hydrogen atom or a methyl group.

6. Compounds according to any of the preceding Claims, wherein the carbon atom bearing the substituent R₅ has the R or S configuration or is a mixture.
5. Compounds of Formula (I) according to any of the preceding Claims, wherein at least one, preferably only one, of the substituents R₁, R₂, R₃ and R₄ on the aromatic ring, represents a hydroxyl, alkoxy or carboxylate group.
8. Compounds of Formula (I) according to any of the preceding Claims, wherein the linear or branched C₁-C₆ alkyl group is the methyl, ethyl, isopropyl or tert.-butyl radical.
9. Compounds of Formula (I) according to any of Claims 1 to 7, wherein the linear or branched (C₁-C₆) alkoxy group is the methoxy, ethoxy, isopropoxy or *tert*.-butoxy group.
10. Pharmaceutical composition comprising at least one compound according to one of Claims 1 to 9, in association with a pharmaceutically acceptable carrier.

20

11. Pharmaceutical composition comprising at least one compound having the following general Formula (I) as the active principle:



wherein

- R₁, R₂, R₃ and R₄, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C₁-C₆) alkyl group, a linear or branched (C₁-C₆) alkoxy group, a linear or branched (C₁-C₆) carboxylate group,

5 - R₅ represents a hydrogen atom or a linear or branched (C₁-C₆) alkyl group,


- m is an integer between 1 and 2, and

- n is an integer between 8 and 20,

stimulating the modulation of the specification of the neural stem cells and/or the differentiation of cells that are precursors of oligodendrocytes in

10 oligodendroglial cells and/or repressing the activation of microglial cells and/or the activation of astrocytes and/or reactive gliosis, in association with a pharmaceutically acceptable carrier.

12. Use of at least one compound having the following general Formula (I):



15

wherein

- R₁, R₂, R₃ and R₄, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C₁-C₆) alkyl group, a linear or branched (C₁-C₆) alkoxy group, a linear or branched (C₁-C₆) carboxylate group,

20 - R₅ represents a hydrogen atom or a linear or branched (C₁-C₆) alkyl group,

- m is an integer between 1 and 2, and


- n is an integer between 8 and 20,

in the preparation of a pharmaceutical composition for the prevention or

25 treatment of diseases of the nervous system altering the oligodendrocytes or

the other cells of the nervous system and/or the inflammation of the nervous system.

13. Use of at least one compound having the following general Formula (I):



5

wherein

- R₁, R₂, R₃ and R₄, identical or different, represent a hydrogen atom, a hydroxyl group, a linear or branched (C₁-C₆) alkyl group, a linear or branched (C₁-C₆) alkoxy group, a linear or branched (C₁-C₆) carboxylate group,

10 - R₅ represents a hydrogen atom or a linear or branched (C₁-C₆) alkyl group,

- m is an integer between 1 and 2, and

- n is an integer between 8 and 20

in the preparation of a pharmaceutical composition for the prevention or the

15 treatment of degenerative neuropathies.

14. Use according to Claim 13, wherein the pharmaceutical composition is intended for the prevention or the treatment of demyelinising or dysmyelinising diseases.

20


15. Use according to Claim 13 or 14, wherein the pharmaceutical composition prevents or treats multiple sclerosis, Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob disease, cerebral vascular accidents or any other damaging attacks to the nervous system.

25

16. Use of at least one compound according to one of the preceding Claims 1-9 for the preparation of a pharmaceutical composition intended to modulate, *in vivo* or *in vitro*, the cellular specification of the neural stem cells, to favour the differentiation and then the survival of the neurones and glial cells in differentiation, to favour the differentiation of precursor cells of oligodendrocytes in mature oligodendrocytes, and/or to reduce the activation of the microglia and/or the activation of the astrocytes and/or the reactive gliosis.

5

10 17. Process for preparing a compound of Formula (I) according to one of the Claims 1 to 9, wherein said process includes the reaction steps of the following scheme:



wherein:

15 - R₁, R₂, R₃, R₄, R₅ and n have the same meaning as described in Claim 2 and
 - R₆ represents a benzyl group or a *tert*-butyldimethylsilyl group.